Literature DB >> 28539294

[Effects of Clostridium butyricum on serum uric acid and inflammatory mediators in rats with hyperuricemia].

Li Wang1, Zhi-Rong Fang, Ya-Ting Shen, Yan-Bo Liu, Li-Li Liu.   

Abstract

OBJECTIVE: To investigate the effects of intragastric administration of Clostridium butyricum in regulating serum uric acid, lipopolysaccharides (LPS), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in rats with hyperuricemia rats.
METHODS: Forty SD rats were randomized into 4 equal groups, namely the normal control group, hyperuricemia model group, benzbromarone (3 mg/kg daily) intervention group and live Clostridium butyricum group (1.5×107 CFU/day). Except for those in the control group, the rats were subjected to intragastric administration of yeast extract and oteracil potassium once daily for 12 weeks to induce hyperuricemia with corresponding treatments. The changes in serum uric acid, lipopolysaccharides , IL-6 and TNF-α in each group were detected.
RESULTS: The serum level of uric acid was significantly higher in rats fed with high-purine diet than in the control rats (P<0.01), demonstrating the successful establishment of hyperuricemia models. In rats with hyperuricemia, serum uric acid level was positively correlated with the levels of LPS, IL-6 and TNF-α, and their serum levels decreased significantly and progressively with time in Benzbromarone group and Clostridium butyricum group. Benzbromarone was more effective in decreasing serum uric acid in the rats, while Clostridium butyricum produced a stronger effect in down-regulating the inflammatory mediators.
CONCLUSION: Chronic inflammatory reaction exists in rats with hyperuricemia. Intragastric administration of Clostridium butyricum can effectively decrease serum uric acid level and inhibit the inflammatory cytokines, and thus contributes to immune homeostasis in the intestines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28539294      PMCID: PMC6780466     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  17 in total

1.  Recovery in humans of intravenously injected isotopic uric acid.

Authors:  J BUZARD; C BISHOP; J H TALBOTT
Journal:  J Biol Chem       Date:  1952-05       Impact factor: 5.157

2.  Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis.

Authors:  R Balfour Sartor
Journal:  Gastroenterology       Date:  2010-10-26       Impact factor: 22.682

3.  Probiotic bacteria stimulate gut epithelial cell proliferation in rat.

Authors:  H Ichikawa; T Kuroiwa; A Inagaki; R Shineha; T Nishihira; S Satomi; T Sakata
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

Review 4.  The role of the gut microbiota in metabolic health.

Authors:  Aafke W F Janssen; Sander Kersten
Journal:  FASEB J       Date:  2015-04-28       Impact factor: 5.191

5.  Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota.

Authors:  Kyoto Imase; Motomichi Takahashi; Akifumi Tanaka; Kengo Tokunaga; Hajime Sugano; Mamoru Tanaka; Hitoshi Ishida; Shigeru Kamiya; Shin'ichi Takahashi
Journal:  Microbiol Immunol       Date:  2008-03       Impact factor: 1.955

6.  Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9.

Authors:  Brian J DeBosch; Oliver Kluth; Hideji Fujiwara; Annette Schürmann; Kelle Moley
Journal:  Nat Commun       Date:  2014-08-07       Impact factor: 14.919

7.  Pro-inflammatory effects of uric acid in the gastrointestinal tract.

Authors:  John K Crane; Krystin M Mongiardo
Journal:  Immunol Invest       Date:  2013-12-30       Impact factor: 3.657

8.  Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine.

Authors:  Yanhong Shi; Ling-Zhi Xu; Kangsheng Peng; Wei Wu; Ruijin Wu; Zhi-Qiang Liu; Gui Yang; Xiao-Rui Geng; Jun Liu; Zhi-Gang Liu; Zhanju Liu; Ping-Chang Yang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

9.  Intestinal Microbiota Distinguish Gout Patients from Healthy Humans.

Authors:  Zhuang Guo; Jiachao Zhang; Zhanli Wang; Kay Ying Ang; Shi Huang; Qiangchuan Hou; Xiaoquan Su; Jianmin Qiao; Yi Zheng; Lifeng Wang; Eileen Koh; Ho Danliang; Jian Xu; Yuan Kun Lee; Heping Zhang
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

Review 10.  Impact of the gut microbiota on inflammation, obesity, and metabolic disease.

Authors:  Claire L Boulangé; Ana Luisa Neves; Julien Chilloux; Jeremy K Nicholson; Marc-Emmanuel Dumas
Journal:  Genome Med       Date:  2016-04-20       Impact factor: 11.117

View more
  2 in total

Review 1.  Potential Molecular Mechanisms of Plantain in the Treatment of Gout and Hyperuricemia Based on Network Pharmacology.

Authors:  Pei Liu; Huachong Xu; Yucong Shi; Li Deng; Xiaoyin Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-22       Impact factor: 2.629

2.  Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia: probiotics increased.

Authors:  Hai-Tao Yang; Wen-Juan Xiu; Jing-Kun Liu; Yi Yang; Xian-Geng Hou; Ying-Ying Zheng; Ting-Ting Wu; Chen-Xin Wu; Xiang Xie
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.